Plot of copy number of chromosome 8 sequences from Affymetrix Genome-Wide Human SNP Array 6.0 data. Chromosomal position (in Mbp from the p terminus) is displayed on the x axis and SNP copy number on the y axis. Three copies of chromosome 8 sequences (from pter to 8q21.12) are consistent with sequences on the extra der(8) whereas two copies (from 8q21.12 to 8qter) are consistent with regions present on the der(12) and unrearranged chromosome. This cannot predict the orientation of segments of chromosome 8. However, for LYN to be in the correct alignment with the break within ETV6 from chromosome 12, at least an inversion of 22.13 Mb (between 8q12.1 and 8q21.12) has occurred. Other genomic imbalances are apparent; peaks of 6 copies (implying microduplications on the additional der(8)) and troughs of single copies (implying deletion of chromosome 8 sequences from either both copies of der(8) or from the der(12), including a deletion at 8q12.1 at the LYN locus). This suggests localised chromothrypsis on chromosome 8 but this cannot be confirmed without sequencing. 
Reverse transcriptase PCR
Supplementary Method 1 Genomic DNA was extracted from bone marrow mononuclear cells, from diagnosis and remission, using the QIAamp® DNA Blood Maxi Kit (Qiagen). Total RNA was extracted from bone marrow mononuclear cells from the patient using the RNeasy Plus kit (Qiagen). RNA was tested for the ETV6-Lyn fusion by reverse-transcriptase PCR, using specific primers for the ETV6 and Lyn genes (as described in Tanaka et al, 2009 ). The ETV6-AML1-positive acute lymphoblastic leukaemia cell line REH was used as a negative control. A 778bp band was detected in the patient sample, but not in the REH cell line. The PCR product was cloned into pCR2.1 using the TOPO TA cloning kit (Invitrogen) and subsequently sequenced using M13 forward and reverse primers.
Primers: ETV6-F: ccctcccaccattgaactgt LYN-R: gcgtagagcctcacgagctt 
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Fusion occurs between ETV6 exon 5 and LYN exon 8. . Data is shown un-normalised to demonstrate error bars of 95% confidence interval using Tukey's Multiple Comparison Test and so cannot be compared directly to the remission sample. The graph shows that dasatinib has a significant effect at all doses and that both low and high doses appear to have a similar effect on cell viability.
One-way ANOVAR and Bartlett's test for equal variances showed a significant difference between treatments (P value <0.0001). Tukey's Multiple Comparison Test revealed significant difference between all concentrations of dasatinib and untreated (p<0.05) but no significance between the effect of different concentrations (p>0.05).
